ChromaDex® and Scripps Research Institute Collaborate on METLIN Metabolite Database Expanded Database to Include Compounds from ChromaDex's Natural Products and Phytochemical Catalog
IRVINE, Calif., May 31 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, announced today that it has formed a collaboration with The Scripps Center for Metabolomics to generate tandem mass spectrometry data for compounds from the ChromaDex natural products and phytochemical catalog.
The Scripps METLIN Metabolite Database is a repository of metabolite information that includes tandem mass spectrometry data for over 55,000 unique and potentially therapeutic compounds. It is a public, web-based database designed for the archiving, visualization, and analysis of metabolite data. The information is provided to facilitate metabolomics experiments by providing scientists with a comprehensive source of structures for potential metabolites of their compounds of interest. An annotated list of known metabolites and their mass, chemical formula, and structure are available on the METLIN website (http://metlin.scripps.edu). The METLIN database was developed and is maintained by the Siuzdak laboratory at the Scripps Research Institute, La Jolla, California.
Currently, there is limited information for natural products in the database. By expanding the population of data, it will increase the knowledge base and visibility for researchers to screen potential compounds for use in areas of clinical interest, such as cancer, heart disease, diabetes, or Alzheimer's.
"We are very excited about expanding the METLIN metabolite database with the ChromaDex phytochemicals. METLIN is currently the largest repository of metabolite tandem mass spectrometry data. This important class of ChromaDex compounds will expand METLIN's compound library and mass spectrometry data to nutraceuticals and many novel plant-related natural products. The importance in the ChromaDex/METLIN partnership is that it will facilitate metabolomics experiments around the world." states Gary Siuzdak Ph.D, Senior Director, Center for Metabolomics and Mass Spectrometry Scripps Research Institute.
Frank Jaksch, Founder and CSO for ChromaDex, stated "Collaborating with Scripps Research Institute with our natural product libraries will further advance small molecule profiling to increase demand for natural product libraries through the ease of the Internet to assist in finding candidate compounds for research and development."
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights. The company recently launched its BluScience™ line of dietary supplements, now available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S. through a distribution agreement with one of the largest pharmaceutical distributors in North America. BluScience™ is also available at a prominent online retailer, as well as a national health and nutrition products retailer. Capitalizing on the diverse potential applications of the product, ChromaDex is also investigating pTeroPure® for the skincare and pharmaceutical markets, among others. A human clinical trial at the University of Mississippi on the benefits of pTeroPure® was recently completed and the results are forthcoming. For more information about pTeroPure® visit www.pteropure.com or call 949-600-9694.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
SOURCE ChromaDex Corporation